HOUSTON and LONDON – 13 June 2018 – Cell Medica (or ‘the Company’), a leader in next generation cellular immunotherapies for the treatment of cancer, today announced the appointment of Julia P. Gregory as a Non-Executive Director and Audit Chair of the Company’s Board of Directors.
Annalisa Jenkins, Chair of Cell Medica, commented:
“The Board of Cell Medica is very pleased to welcome Julia at such an important time for the company. She brings significant experience in biopharma corporate strategy and financing as well as a deep knowledge of the U.S. investor community and regulation. Julia will play an important role with the Board as we move forward with our innovative cell-based platforms that have the potential to deliver a dramatic impact on the lives of cancer patients.”
Julia Gregory commented:
“I am delighted to join Cell Medica as the company brings a new generation of CAR and TCR cell therapies into the clinical stage of development. I believe that continued progress with these novel products will create new strategic partnering and financing opportunities for Cell Medica and I look forward to working with the Board and management to realize the full potential of these transformative therapies for patients.”
Ms. Gregory has extensive experience in senior roles in the biopharmaceutical industry as well as more than 20 years of investment banking experience. She currently serves as a non-executive director of several biopharmaceutical companies, including Sosei Group Corporation and Biohaven Pharmaceuticals. Ms. Gregory is also Chairman and CEO of the biotechnology financial and management advisory firm Isometry Advisors, Inc.
In her previous executive roles, Ms. Gregory served as Chief Executive Officer, Chief Financial Officer and Board Director of ContraFect Corporation; President and CEO of Five Prime Therapeutics; and Executive Vice President, Corporate Development and Chief Financial Officer of Lexicon Pharmaceuticals, Inc. Her corporate development experience includes leading transactions for significant strategic partnerships including development and licensing agreements with GlaxoSmithKline, Human Genome Sciences, Genentech, Bristol-Myers Squibb Company and Takeda Pharmaceutical Company Limited.
As CFO at Lexicon, she led the company’s $220 million public offering and was involved in the creation of Lexicon’s $500 million private equity plan with Invus, LLP. Prior to her leadership positions in the biopharmaceutical industry, Ms. Gregory was an investment banker at Dillon, Read & Co. and subsequently at Punk, Ziegel & Company, where she served as the head of investment banking and head of its life sciences practice.
Ms. Gregory holds an M.B.A. from the Wharton School at the University of Pennsylvania and a B.A. from George Washington University.